Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:ASNDNASDAQ:ITCINYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$63.00-1.3%$62.61$47.86▼$107.37$3.52B0.28608,622 shs977,978 shsASNDAscendis Pharma A/S$176.90+3.6%$164.91$111.09▼$183.00$10.44B0.37495,701 shs415,686 shsITCIIntra-Cellular Therapies$131.87$131.87$66.26▼$131.98$14.05B0.691.57 million shsN/ARDYDr. Reddy's Laboratories$15.22+0.2%$14.41$12.26▼$16.89$12.68B0.331.51 million shs1.50 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%-4.04%+5.42%-7.95%+18.60%ASNDAscendis Pharma A/S0.00%-0.12%+5.66%+2.84%+38.57%ITCIIntra-Cellular Therapies0.00%0.00%0.00%+0.17%+74.71%RDYDr. Reddy's Laboratories0.00%-5.92%+4.87%+10.64%+7.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.4603 of 5 stars3.53.00.00.01.92.50.0ASNDAscendis Pharma A/S3.2411 of 5 stars4.53.00.00.01.51.70.6ITCIIntra-Cellular Therapies0.6875 of 5 stars1.10.00.04.50.01.70.6RDYDr. Reddy's Laboratories2.7137 of 5 stars2.53.01.70.03.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.2376.56% UpsideASNDAscendis Pharma A/S 3.00Buy$220.6724.74% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideRDYDr. Reddy's Laboratories 3.00Buy$16.9511.35% UpsideCurrent Analyst Ratings BreakdownLatest ACLX, ITCI, RDY, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025ACLXArcellxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$110.006/16/2025ACLXArcellxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/5/2025RDYDr. Reddy's LaboratoriesHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/5/2025RDYDr. Reddy's LaboratoriesHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$14.44 ➝ $16.906/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M32.17N/AN/A$8.41 per share7.49ASNDAscendis Pharma A/S$393.54M27.48N/AN/A($1.88) per share-94.10ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RDYDr. Reddy's Laboratories$3.81B3.33$1.03 per share14.71$4.73 per share3.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$2.99N/AN/AN/A-211.46%-35.27%-22.73%8/14/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$6.28N/A737.08N/A-93.22%N/A-33.29%9/2/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/ARDYDr. Reddy's Laboratories$663M$0.6623.0618.566.2417.38%17.98%12.24%7/25/2025 (Estimated)Latest ACLX, ITCI, RDY, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.080.53%N/A12.12%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.934.93ASNDAscendis Pharma A/SN/A1.040.71ITCIIntra-Cellular TherapiesN/A7.667.51RDYDr. Reddy's Laboratories0.021.921.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ASNDAscendis Pharma A/SN/AITCIIntra-Cellular Therapies92.33%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%ASNDAscendis Pharma A/S40.00%ITCIIntra-Cellular Therapies2.60%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.51 millionOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRDYDr. Reddy's Laboratories27,811834.77 million818.08 millionOptionableACLX, ITCI, RDY, and ASND HeadlinesRecent News About These CompaniesDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Ritholtz Wealth ManagementJune 19 at 3:52 AM | marketbeat.comGAMMA Investing LLC Purchases 66,049 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)June 17 at 3:14 AM | marketbeat.comRhumbline Advisers Sells 86,773 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)June 14, 2025 | marketbeat.comStanley Laman Group Ltd. Makes New $1.85 Million Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)June 13, 2025 | marketbeat.comDr. Reddy's Laboratories rallies Tuesday, outperforms competitorsJune 10, 2025 | marketwatch.comDr. Reddy's Laboratories Reaches Analyst Target PriceJune 8, 2025 | nasdaq.comHSBC Upgrades Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY)June 6, 2025 | msn.comDr. Reddy's Laboratories (NYSE:RDY) Upgraded by Hsbc Global Res to "Strong-Buy" RatingJune 6, 2025 | marketbeat.comHSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from HoldJune 5, 2025 | msn.comDr. Reddy's Laboratories rallies Thursday, outperforms competitorsJune 5, 2025 | marketwatch.comHSBC upgrades Dr Reddy’s on weight loss drug semaglutide-driven earnings reboundJune 5, 2025 | in.investing.comDr. Reddy’s stock rises on biosimilar collaboration with AlvotechJune 5, 2025 | investing.comDr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up - Time to Buy?June 5, 2025 | marketbeat.comRDY & ALVO Ink Collaboration Deal for Merck's Keytruda BiosimilarJune 5, 2025 | zacks.comDr. Reddy's Laboratories (NYSE:RDY) Raised to "Buy" at HSBCJune 5, 2025 | marketbeat.comAlvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)June 5, 2025 | businesswire.comAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)June 5, 2025 | finance.yahoo.comAlvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)June 5, 2025 | msn.comDr. Reddy’s Labs ADR Stock Price HistoryJune 4, 2025 | investing.comDr. Reddy's Laboratories rises Wednesday, underperforms marketJune 4, 2025 | marketwatch.comTwo Sigma Advisers LP Acquires 23,700 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)June 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACLX, ITCI, RDY, and ASND Company DescriptionsArcellx NASDAQ:ACLX$63.00 -0.82 (-1.28%) Closing price 04:00 PM EasternExtended Trading$63.02 +0.02 (+0.04%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Ascendis Pharma A/S NASDAQ:ASND$176.90 +6.19 (+3.63%) Closing price 04:00 PM EasternExtended Trading$176.91 +0.01 (+0.01%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Dr. Reddy's Laboratories NYSE:RDY$15.22 +0.03 (+0.21%) Closing price 03:59 PM EasternExtended Trading$15.23 +0.01 (+0.05%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
